{"groups":[{"description":"NONMYELOABLATIVE CONDITIONING: Patients receive fludarabine IV over 1 hour on days -6 to -2 and cyclophosphamide IV over 1 hour on days -6 and -5. Patients undergo total body irradiation on day -1.\n\nTRANSPLANTATION: Patients undergo BMT, from an HLA-haploidentical donor, on day 0.\n\nPOST-TRANSPLANT IMMUNOSUPPRESSION: Patients receive cyclophosphamide IV over 1 hour on day 3.\n\nGRAFT-VERSUS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV over 1-2 hours and then tacrolimus PO, once tolerated, on days 4-180, with taper on day 86 in the absence of graft-versus-host disease. Patients also receive mycophenolate mofetil PO three times daily on days 4-35.","id":"FG000","title":"Treatment (Nonmyeloablative HSCT)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"55"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"55"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}